Which manufacturer is Regorafenib?

Regorafenib(Regorafenib)The original drug was developed and produced by Bayer Pharmaceuticals in Germany. It has been approved by the US Food and Drug Administration (FDA) for marketing. The trade name is Stivarga, used to treat patients with Patients with metastatic colorectal cancer (CRC), metastatic gastrointestinal stromal tumor (GIST), and hepatocellular carcinoma (HCC) , these patients may have previously received chemotherapy with other drugs.

Patients treated with regorafenib must be prescribed by a doctor experienced in treating cancer. This drug is only available with a prescription. Regofenibis usuallyavailable as tablets (40 mg). It is taken in a 4-week treatment cycle, with the recommended starting dose being 160 mg (4 tablets) once daily for three weeks, followed by one week without medication. Doses should be taken at the same time each day with a small meal. Treatment should continue as long as the patient benefits from treatment or until side effects become too severe. If patients experience certain side effects, treatment may need to be interrupted or stopped, or the dose may need to be reduced.

RegofenibThe original drug has been launched in China and has entered the scope of Class B medical insurance. Reimbursement is limited to patients who meet the indications. SpecificationThe price of each box of 40mg*28 tablets is around RMB 5,000. The reimbursement ratio is different in different regions, and the price after reimbursement is different. The Turkish version of regorafeniboriginal drug specifications 40mg*28 tablets sold overseas is priced around RMB 6,400 per box (the price may fluctuate due to exchange rates). There are also generic regorafenib drugs produced in other countries, and their drug ingredients are basically the same as those of the original drug. The price of a box of 40mg*90 tablets produced by a Bangladesh pharmaceutical factory is around 2,900 yuan (the price may fluctuate due to exchange rates).